Gail Wygant

1.5k total citations
41 papers, 1.2k citations indexed

About

Gail Wygant is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Gail Wygant has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 19 papers in Internal Medicine and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Gail Wygant's work include Venous Thromboembolism Diagnosis and Management (19 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Diabetes Treatment and Management (8 papers). Gail Wygant is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (19 papers), Atrial Fibrillation Management and Outcomes (17 papers) and Diabetes Treatment and Management (8 papers). Gail Wygant collaborates with scholars based in United States, United Kingdom and Germany. Gail Wygant's co-authors include Ole Hauch, Matthew W. Reynolds, Luba Nalysnyk, Kyle Fahrbach, Joseph Menzin, Mark Friedman, Catherine Cella, Rhonda Estok, Lauren A. Hoffman and Vincent J. Willey and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and Cancer Research.

In The Last Decade

Gail Wygant

39 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gail Wygant United States	18	784	476	218	189	153	41	1.2k
Hemant Phatak United States	22	1.0k 1.3×	390 0.8×	122 0.6×	187 1.0×	277 1.8×	87	1.7k
Peter T. Sawicki Germany	19	637 0.8×	157 0.3×	340 1.6×	137 0.7×	224 1.5×	44	1.4k
Gianluigi Devoto Italy	9	992 1.3×	675 1.4×	62 0.3×	316 1.7×	59 0.4×	12	1.5k
David Battleman United States	17	607 0.8×	191 0.4×	55 0.3×	209 1.1×	117 0.8×	32	1.1k
Ole Hauch United States	23	1.2k 1.5×	800 1.7×	55 0.3×	353 1.9×	228 1.5×	53	1.7k
M Poggi Italy	12	964 1.2×	706 1.5×	90 0.4×	208 1.1×	59 0.4×	26	1.5k
C. Seth Landefeld United States	6	592 0.8×	390 0.8×	53 0.2×	173 0.9×	108 0.7×	10	989
DaJuanicia N. Simon United States	19	1.7k 2.1×	355 0.7×	121 0.6×	211 1.1×	180 1.2×	34	2.1k
Niels Gadsbøll Denmark	20	2.0k 2.5×	336 0.7×	96 0.4×	389 2.1×	163 1.1×	45	2.4k
Elena Birman-Deych United States	6	743 0.9×	215 0.5×	67 0.3×	152 0.8×	133 0.9×	7	1.5k

Countries citing papers authored by Gail Wygant

Since Specialization

Citations

This map shows the geographic impact of Gail Wygant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail Wygant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail Wygant more than expected).

Fields of papers citing papers by Gail Wygant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail Wygant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail Wygant. The network helps show where Gail Wygant may publish in the future.

Co-authorship network of co-authors of Gail Wygant

This figure shows the co-authorship network connecting the top 25 collaborators of Gail Wygant. A scholar is included among the top collaborators of Gail Wygant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail Wygant. Gail Wygant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guo, Jian, Patrick Hlavacek, Gail Wygant, et al.. (2020). Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States. Journal of Thrombosis and Thrombolysis. 50(2). 386–394. 15 indexed citations

Lanitis, Tereza, Xiaoyan Li, Gail Wygant, et al.. (2019). Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. Applied Health Economics and Health Policy. 18(4). 533–545. 16 indexed citations

Guo, Jennifer D., Patrick Hlavacek, Gail Wygant, et al.. (2019). Abstract 3367: Treatment patterns in patients with cancer-associated venous thromboembolism in the US: A real world retrospective database analysis. Cancer Research. 79(13_Supplement). 3367–3367. 1 indexed citations

Weycker, Derek, Xiaoyan Li, Gail Wygant, et al.. (2018). SAFETY AND EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN THE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM. Journal of the American College of Cardiology. 71(11). A1953–A1953. 1 indexed citations

Chen, Wen, et al.. (2018). Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. Journal of Comparative Effectiveness Research. 7(8). 785–795. 1 indexed citations

Gordon, Jason, et al.. (2017). Assessing The Economic Impact Of The Introduction Of Daclatasvir In Combination With Asunaprevir For The Treatment Of Chronic Hepatitis C In China. Value in Health. 20(9). A782–A782.

Ward, Thomas, et al.. (2016). Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value in Health Regional Issues. 12. 1–6. 3 indexed citations

Swallow, Elyse, et al.. (2015). Daclatasvir +Asunaprevir Versus Sofosbuvir/Ledipasvir for The Treatment of Chronic Hepatitis C Genotype 1 In Japanese Patients: A Matching-Adjusted Indirect Comparison. Value in Health. 18(7). A576–A576. 2 indexed citations

Tiwari, Divya, Claudine Jurkovitz, J. Richard Bowen, et al.. (2014). Risk factors for cardiovascular events and bleeding complications following non-cardiac surgery or procedure in patients with drug eluting stent placement. Heart Asia. 6(1). 69–75. 2 indexed citations

10.

Orme, Michelle, et al.. (2014). A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetology & Metabolic Syndrome. 6(1). 73–73. 18 indexed citations

11.

McAdam‐Marx, Carrie, Brandon K. Bellows, Sudhir Unni, et al.. (2014). Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study). International Journal of Clinical Practice. 68(11). 1309–1317. 20 indexed citations

12.

McAdam‐Marx, Carrie, Brandon K. Bellows, Sudhir Unni, et al.. (2014). Impact of Adherence and Weight Loss on Glycemic Control in Patients with Type 2 Diabetes: Cohort Analyses of Integrated Medical Record, Pharmacy Claims, and Patient-Reported Data. Journal of Managed Care Pharmacy. 20(7). 691–700. 34 indexed citations

13.

Bergenheim, Klas, Susan Grandy, & Gail Wygant. (2013). Cost of Achieving Relevant Composite Endpoint of HbA1c<7%, No Hypoglycaemia and Weight Loss of ≥3% in a 52 Week Post-Hoc Analysis of Dapagliflozin Versus Glipizide. Value in Health. 16(7). A439–A439. 1 indexed citations

14.

Wong, Nathan D., Diana Glovaci, Shaista Malik, et al.. (2012). Global cardiovascular disease risk assessment in United States adults with diabetes. Diabetes and Vascular Disease Research. 9(2). 146–152. 50 indexed citations

15.

Knight, Kevin, John Wong, Ole Hauch, et al.. (2005). Economic and Utilization Outcomes Associated with Choice of Treatment for Venous Thromboembolism in Hospitalized Patients. Value in Health. 8(3). 191–200. 29 indexed citations

16.

Harley, Carolyn, et al.. (2005). Anticoagulation therapy in patients with chronic atrial fibrillation: a retrospective claims data analysis. Current Medical Research and Opinion. 21(2). 215–222. 10 indexed citations

17.

Samsa, Greg, David B. Matchar, Rowena J Dolor, et al.. (2004). A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation.. Health and Quality of Life Outcomes. 2(1). 22–22. 82 indexed citations

18.

Wittkowsky, Ann K., Stephen J. Boccuzzi, Jenifer Wogen, et al.. (2004). Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(12). 1668–1674. 60 indexed citations

19.

Reynolds, Matthew W., Kyle Fahrbach, Ole Hauch, et al.. (2004). Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation. CHEST Journal. 126(6). 1938–1945. 200 indexed citations

20.

Willey, Vincent J., Michael Bullano, Ole Hauch, et al.. (2004). Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clinical Therapeutics. 26(7). 1149–1159. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact